Orthofix M6-C artificial cervical disc isn't inferior to ACDF, study finds — 6 insights

Written by Angie Stewart | April 04, 2019 | Print  |

Patients treated with Orthofix's M6-C artificial cervical disc reported higher pain, function and quality of life scores than patients who underwent anterior cervical discectomy and fusion, according to results of a U.S. Investigational Device Exemption study.

Researchers conducted a clinical trial across 23 U.S. sites.

Six findings:

1. The M6-C artificial cervical disc was linked to reduced pain and opioid use compared to ACDF patients. The control group continued using opioids at seven times the rate of M6-C patients at 24 months.

2. The M6-C disc patients had an 86.8 percent overall success rate at 24 months, compared to 79.3 percent in the control group.

3. The average surgery time was 74.5 minutes for M6-C patients and 120.2 minutes for ACDF patients.

4. Subsequent surgery was necessary in 4.8 percent of ACDF patients and 1.9 percent of M6-C disc patients.

5. About 4 percent of patients in the M6-C group experienced serious adverse events related to the device or procedure, compared to about 6 percent in the ACDF group.

6. Cervical disc replacement with the M6-C disc is on-par with ACDF treatment, researchers concluded.

More articles on devices:
What drives orthopedic, spine device company M&A today and what to watch for through 2020
Medtronic requests review in $23M patent infringement decision
Stryker makes 2 legal leadership changes

 

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers